Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 39, Issue 4, Pages 679-683Publisher
WILEY
DOI: 10.1002/hed.24662
Keywords
chemoradiotherapy; carcinoma; squamous cell; skin neoplasms; prospective studies
Categories
Funding
- Amgen
- Roche Australia
- Merck, Sharp and Dohme
- AstraZeneca
- Ipsen
- Roche
Ask authors/readers for more resources
Background. The purpose of this study was to present our evaluation of the outcomes of concurrent chemoradiotherapy (CRT) in patients with locally advanced cutaneous squamous cell carcinoma (SCC). Methods. This was a prospective phase II study. The primary endpoint was complete response (CR). Patients with locally/regionally advanced cutaneous SCC deemed unsuitable for surgery received definitive radiotherapy (RT; 70 Gy in 35fractions) and concurrent weekly platinumbased chemotherapy (cisplatin 40 mg/m2 or carboplatin area under the curve 2). Results. Twenty-one patients were enrolled in this study. Eighteen patients had a locally advanced primary or nodal disease in the head and neck region with 66% having stage IV nonmetastatic disease. Of 19 evaluable patients, 10 achieved a CR to definitive CRT with 2 further patients rendered disease-free by salvage surgery for an overall CR of 63%. Conclusion. This is the only prospective series of CRT for cutaneous SCC. A high CR rate was documented in patients with locoregional advanced disease who were unable to undergo surgery. (C) 2016 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available